Obsidian®ASG in anastomotic healing after rectal cancer resection—OBANORES: a prospective clinical feasibility study
International Journal of Colorectal Disease · 2025
DOI: 10.1007/s00384-025-04881-2 ↗Kurz gefasst
Klinische Studie in der Zeitschrift International Journal of Colorectal Disease, 2025. Verfasst von Thomas Nikolas Valsamidis und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Aarhus University Hospital, Aarhus, Denmark. Hauptthemen laut MEDLINE: Rectal Neoplasms, Wound Healing, Blood Platelets. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Kræftens Bekæmpelse, Aarhus Universitet.
Abstract (Originalsprache)
Purpose
Anastomotic leakage following rectal cancer resection is a serious complication. Despite efforts to prevent it, the risk remains high. Obsidian®ASG, an AUTOLOGOUS fibrin matrix with thrombocytes derived from the patient’s blood, shows promise but has not been thoroughly tested in rectal anastomosis. The aim of this study was to assess the feasibility of using Obsidian®ASG as a supplement in rectal anastomosis creation during minimally invasive rectal cancer resection.
Methods
This prospective IDEAL stage 2a development cohort study included 50 patients undergoing rectal cancer resection with anastomosis using minimally invasive surgery at Aarhus University Hospital, Denmark. Obsidian®ASG application was assessed using a predefined rating scale: “Complete” (applied in all three prescribed steps), “Almost complete” (applied in at least the first or second step), and “Incomplete” (all others). Feasibility required “Complete” or “Almost complete” application in at least 90% of patients.
Results
Obsidian®ASG application was “Complete” in 15 cases (30%) and “Almost complete” in 35 cases (70%), meeting feasibility criteria in all patients. No “Incomplete” applications occurred. Difficulties in achieving “Complete” application included anatomical constraints, material depletion, machine error, and time constraints.
Conclusion
Obsidian®ASG was successfully applied in all patients undergoing minimally invasive rectal cancer surgery. These findings suggest its feasibility, but further large-scale, multi-center randomized trials are needed to fully assess its potential benefits for patient outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Surgery, Aarhus University Hospital, Aarhus, Denmark.
- Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.
- Department of Surgery, Aarhus University Hospital, Aarhus, Denmark. lene.h.iversen@clin.au.dk.
- Department of Clinical Medicine, Aarhus University, Aarhus, Denmark. lene.h.iversen@clin.au.dk.
Förderung
- Kræftens Bekæmpelse
- Aarhus Universitet
Zitieren
APA
Valsamidis, T. N., Tøttrup, A., Ljungmann, K., Avlund, T. H., Harsløf, S., Buchard, C., & Iversen, L. H. (2025). Obsidian®ASG in anastomotic healing after rectal cancer resection—OBANORES: a prospective clinical feasibility study. International Journal of Colorectal Disease. https://doi.org/10.1007/s00384-025-04881-2
Vancouver
Valsamidis TN, Tøttrup A, Ljungmann K, Avlund TH, Harsløf S, Buchard C, et al. Obsidian®ASG in anastomotic healing after rectal cancer resection—OBANORES: a prospective clinical feasibility study. International Journal of Colorectal Disease. 2025. doi:10.1007/s00384-025-04881-2
BibTeX
@article{Valsamidis2025,
author = {Valsamidis, Thomas Nikolas and Tøttrup, Anders and Ljungmann, Ken and Avlund, Tue Højslev and Harsløf, Sanne and Buchard, Charlotte and Iversen, Lene Hjerrild},
title = {Obsidian®ASG in anastomotic healing after rectal cancer resection—OBANORES: a prospective clinical feasibility study},
journal = {International Journal of Colorectal Disease},
year = {2025},
doi = {10.1007/s00384-025-04881-2}
}
EUVIMED